



Supplementary Figure S6 The relationship between CLU expression and the extent of immune cell infiltration across multiple tumor types using the TIMER database

CLU was correlated with the level of CD8⁺ T cell infiltration in 10 tumor types, CD4⁺ T cell infiltration in 23 tumor types, macrophage infiltration in 21 tumor types, neutrophil infiltration in 12 tumor types, and DC infiltration in 20 tumor types. (Marked with the red asterisk)


ACC




BLCA




BRCA




BRCA-Basal




BRCA-Luminal




BRCA-Her2




CESC




CHOL




COAD




DLBC




ESCA




GBM




HNSC




HNSC-HPVpos




HNSC-HPVneg




KICH




KIRC




KIRP




LGG




LHC




LUAD




LUSC




MESO




OV




PAAD




PCPG




PRAD




READ




SARC




SKCM




SKCM-Primary




SKCM-Metastasis




STAD




TGCT




THCA




THYM



UCEC



UCS



UVM




Figure S6 The relationship between CLU expression and the extent of immune cell infiltration across multiple tumor types using the TIMER database. CLU was correlated with the level of CD8⁺ T cell infiltration in 10 tumor types, CD4⁺ T cell infiltration in 23 tumor types, macrophage infiltration in 21 tumor types, neutrophil infiltration in 12 tumor types, and DC infiltration in 20 tumor types (marked with the red asterisk). partial.cor, partial correlation; CD, cluster of differentiation;; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large b-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; HPVpos, human papillomavirus positive; HPVneg, human papillomavirus negative; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectal adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma; CLU, clusterin; TIMER, Tumor Immune Estimation Resource; DC, dendritic cell.